دورية أكاديمية
XBB.1.16-RBD-based trimeric protein vaccine can effectively inhibit XBB.1.16-included XBB subvariant infection.
| العنوان: | XBB.1.16-RBD-based trimeric protein vaccine can effectively inhibit XBB.1.16-included XBB subvariant infection. |
|---|---|
| المؤلفون: | Peng D; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., He C; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Chen Z; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Lei H; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Huang X; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Ye C; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Wang B; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Hao Y; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Du X; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Lu S; National Kunming High-Level Biosafety Primate Research Center, Institute of Medical Biology Chinese Academy of Medical Sciences and Peking Union Medical College Kunming Yunnan China., Hu H; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Cheng W; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Dong H; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Lei J; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Zhou X; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China., Song X; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China.; WestVac Biopharma Co. Ltd. Chengdu China., Lu G; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China.; WestVac Biopharma Co. Ltd. Chengdu China., Wei X; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China.; WestVac Biopharma Co. Ltd. Chengdu China. |
| المصدر: | MedComm [MedComm (2020)] 2024 Aug 16; Vol. 5 (9), pp. e687. Date of Electronic Publication: 2024 Aug 16 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons, Inc Country of Publication: China NLM ID: 101769925 Publication Model: eCollection Cited Medium: Internet ISSN: 2688-2663 (Electronic) Linking ISSN: 26882663 NLM ISO Abbreviation: MedComm (2020) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Beijing, China] : John Wiley & Sons, Inc. [2020]- |
| مستخلص: | The newly identified XBB.1.16-containing sublineages, including XBB.1.5, have become the prevailing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in circulation. Unlike previous Omicron XBB variants (e.g., XBB.1.5 and XBB.1.9) harboring the F486P substitution, XBB.1.16 also carries a T478R substitution in the receptor-binding domain (RBD). Numerous researchers have delved into the high transmissibility and immune evasion of XBB.1.16 subvariant. Therefore, developing a new vaccine targeting XBB.1.16, including variants of concern (VOCs), is paramount. In our study, we engineered a recombinant protein by directly linking the S-RBD sequence of the XBB.1.16 strain of SARS-CoV-2 to the sequences of two heptad repeat sequences (HR1 and HR2) from the SARS-CoV-2 S2 subunit. Named the recombinant RBD Competing Interests: This work was supported by the WestVac Biopharma Co. Ltd. Guangwen Lu and Xiawei Wei, who are also working at the WestVac Biopharma Co. Ltd. The remaining authors declare no conflicts of interest. (© 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.) |
| References: | Sci Transl Med. 2023 Mar;15(685):eadd6383. (PMID: 36454813) J Struct Biol. 2007 Jan;157(1):38-46. (PMID: 16859925) Signal Transduct Target Ther. 2021 Sep 16;6(1):343. (PMID: 34531369) Science. 2022 Nov 11;378(6620):619-627. (PMID: 36264829) Parasit Vectors. 2023 Aug 8;16(1):269. (PMID: 37553591) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Lancet Infect Dis. 2023 Jun;23(6):655-656. (PMID: 37148902) Lancet Infect Dis. 2023 Dec;23(12):1349-1359. (PMID: 37478877) Lancet. 2021 May 15;397(10287):1819-1829. (PMID: 33964222) Nature. 2020 May;581(7807):215-220. (PMID: 32225176) J Struct Biol. 2015 Nov;192(2):216-21. (PMID: 26278980) Nat Methods. 2017 Mar;14(3):290-296. (PMID: 28165473) Lancet. 2023 Sep 30;402(10408):1127-1128. (PMID: 37777324) BMJ. 2023 Jul 25;382:e075286. (PMID: 37491022) Nature. 2021 Feb;590(7844):E23. (PMID: 33469221) MedComm (2020). 2023 Mar 10;4(2):e238. (PMID: 36911160) Nature. 2020 Oct;586(7830):572-577. (PMID: 32726802) Vaccines (Basel). 2023 Nov 11;11(11):. (PMID: 38006043) Nat Med. 2023 Jan;29(1):247-257. (PMID: 36265510) Clin Cancer Res. 2006 Jan 15;12(2):465-72. (PMID: 16428488) Sci Rep. 2022 Oct 7;12(1):15606. (PMID: 36207324) J Infect Dis. 2023 Jul 14;228(2):149-159. (PMID: 36861215) Cell Mol Immunol. 2023 Aug;20(8):969-971. (PMID: 37156807) Biochem J. 2021 Dec 22;478(24):4169-4185. (PMID: 34783343) Nat Commun. 2022 Sep 17;13(1):5459. (PMID: 36115859) Nature. 2022 Aug;608(7923):603-608. (PMID: 35790190) Nat Med. 2023 Feb;29(2):344-347. (PMID: 36473500) |
| فهرسة مساهمة: | Keywords: XBB.1.16 variant; heterologous booster; recombinant RBD‐HR protein |
| تواريخ الأحداث: | Date Created: 20240819 Latest Revision: 20240820 |
| رمز التحديث: | 20240820 |
| مُعرف محوري في PubMed: | PMC11329747 |
| DOI: | 10.1002/mco2.687 |
| PMID: | 39156763 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2688-2663 |
|---|---|
| DOI: | 10.1002/mco2.687 |